---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-055201"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:40:17.344581+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q1 revenue $964M (+7%), EPS $2.81; cuts 2024 revenue/EPS guidance on FX and visit slowdown

## Summary
- Q1 revenue $964M (+7% as reported and organic); EPS $2.81 (+10% reported, +9% comparable).
- CAG Diagnostics recurring revenue grew 7% as reported and organic; global premium instrument installed base up 11% YoY.
- FY2024 revenue guidance lowered to $3,895M-$3,965M (prior $3,930M-$4,040M); EPS guidance lowered to $10.82-$11.20.
- Guidance cut reflects ~$35M FX headwind and reduction of 1% from high end of organic growth range due to US clinical visit moderation.
- Gross margin improved 120bps to 61.5%; operating margin contracted 10bps to 31.0% due to lapping a Q1 2023 customer contract resolution payment.

## SEC filing metadata
- accession: 0001104659-24-055201
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465924055201/0001104659-24-055201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465924055201/tm2413183d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-055201
- JSON: https://secwatch.observer/filing/0001104659-24-055201.json
- Plain text: https://secwatch.observer/filing/0001104659-24-055201.txt

## Key facts
- Earnings Releases
  IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2024 results: revenue $964 million, EPS $2.81. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $964 million
  - EPS: $2.81
  - Guidance: reaffirmed
  - Result: reported results
  source text: Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $964 million for the first quarter of 2024, an increase of 7% as reported and organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and organic, and Water revenue growth
  evidence_url: https://www.sec.gov/Archives/edgar/data/874716/000110465924055201/0001104659-24-055201-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.